Urine Prostate Screening Integrated With MRI for Early Detection of Prostate Cancer, UPRISE Trial

Starting soon · Not applicable

Conditions studied: Prostate Carcinoma

In brief

This clinical trial tests how well a urine prostate cancer screening test, My Prostate Score 2 (MPS2), integrated with magnetic resonance imaging (MRI) works for early detection of prostate cancer. MPS2 is an investigational urine-based test designed to help identify the likelihood of having aggressive prostate cancer. MPS2 testing works by measuring specific early detection biomarkers that include genetic information. This next-generation test aims to address a major challenge in prostate cancer care-detecting only the cancers that truly need treatment. Results may lead to paradigm shifts in early detection algorithms and reduce reliance on MRI and biopsy.

Key facts

Study ID

NCT07526545

Run by

University of Michigan Rogel Cancer Center

People needed

800

Starts

2026-09-01

Expected to finish

2030-03-01

Last updated by the study team

2026-06-09

Who can join

Age: 50 and older, up to 75. Sex: male. Healthy volunteers: accepted.

You may qualify if…

• Males aged 50-75
• PSA 3-20 ng/ml within the previous 3 months
• Fit to undergo all procedures listed in protocol per treating physician's discretion
• No prostate biopsy in the past 4 years
• No prostate MRI in the past 2 years
• Able to provide written informed consent

You may not qualify if…

• Prior diagnosis of prostate cancer
• Contraindication to MRI (e.g. claustrophobia, pacemaker)
• Contraindication to prostate biopsy
• Previous hip replacement surgery, metallic hip replacement or extensive pelvic orthopaedic metal work

Where it is running

• University of Michigan Rogel Cancer Center — Ann Arbor, Michigan, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.